A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 1
- Sponsors LEO Pharma
- 15 Jun 2017 According to a LEO Pharma media release, first patient has been dosed.
- 08 Jun 2017 Status changed from not yet recruiting to recruiting.
- 24 Apr 2017 Status changed from planning to not yet recruiting.